Margolin, Sara, et al. “A Randomised Feasibility Phase II Study (SBG 2004-1) With Dose-Dense Tailored Epirubicin, Cyclophoshamide (EC) Followed by Docetaxel (T) or Fixed Dosed Dose-Dense EC T Versus T, Doxorubicin and C (TAC) in Node-Positive Breast Cancer”. Acta Oncologica, vol. 50, no. 1, Jan. 2011, pp. 35-41, doi:10.3109/0284186X.2010.535847.